The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.

Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

An implantable medical device is provided for controlled drug delivery within the bladder, or other body vesicle. The device may include at least one drug reservoir component comprising a drug; and a vesicle retention frame which comprises an elastic wire having a first end, an opposing second end, and an intermediate region therebetween, wherein the drug reservoir component is attached to the intermediate region of the vesicle retention frame. The retention frame prevents accidental voiding of the device from the bladder, and it preferably has a spring constant selected for the device to effectively stay in the bladder during urination while minimizing the irritation of the bladder.

An implantable medical device is provided for controlled drug delivery within the bladder, or other body vesicle. The device may include at least one drug reservoir component comprising a drug; and a vesicle retention frame which comprises an elastic wire having a first end, an opposing second end, and an intermediate region therebetween, wherein the drug reservoir component is attached to the intermediate region of the vesicle retention frame. The retention frame prevents accidental voiding of the device from the bladder, and it preferably has a spring constant selected for the device to effectively stay in the bladder during urination while minimizing the irritation of the bladder.

A moisturizing composition for delivery of lidocaine is provided with viscosity thickening provided by the use of sclerotium gum and hydroxyethylcellulose in approximately equivalent amounts in a slightly acidic vehicle without anionic compounds.

A moisturizing composition for delivery of lidocaine is provided with viscosity thickening provided by the use of sclerotium gum and hydroxyethylcellulose in approximately equivalent amounts in a slightly acidic vehicle without anionic compounds.

The present invention relates to an improved wound product that is equivocal to manuka honey in antimicrobial and wound healing effectiveness, but may be mixed with a therapeutic anesthetic, may have a fragrance, may be stored in a spray dispenser, may be used with a straw, and is applied as a foam. This provides the option of a straw being attached to the dispenser hole for dispensing honey foam for deep tunneling wound. It may also be sprayed directly on the wound or burn, or be sprayed on a sterile sponge for application.

The present invention relates to an improved wound product that is equivocal to manuka honey in antimicrobial and wound healing effectiveness, but may be mixed with a therapeutic anesthetic, may have a fragrance, may be stored in a spray dispenser, may be used with a straw, and is applied as a foam. This provides the option of a straw being attached to the dispenser hole for dispensing honey foam for deep tunneling wound. It may also be sprayed directly on the wound or burn, or be sprayed on a sterile sponge for application.

Provided herein is a topical antibiotic composition that includes an external antibiotic agent, one or more pharmaceutically acceptable excipients, and at least one of a cannabinoid, terpene, and flavonoid. Also provided is a method that includes topically administering to a skin surface of a subject (e.g., human) the topical antibiotic composition.